The free trade agreement between Australia and the United States

British Medical Journal

Volumn 328, Issue 7451, 2004, Pages 1271-1272

  Drahos, Peter ^a   Henry, David ^b  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GENERIC DRUG;

AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; DRUG MANUFACTURE; EDITORIAL; HEALTH CARE POLICY; PRIORITY JOURNAL; PUBLIC HEALTH; UNITED STATES;

EID: 2542564206     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.328.7451.1271     Document Type: Editorial

References (4)

1. Australian Department of Foreign Affairs and Trade. Australia-United States Free Trade Agreement. www.dfat.gov.au/trade/negotiations/us_fta/text/ index.html (accessed 17 Mar 2004).
2. Henry DA, Birkett D. Changes to the pharmaceutical benefits scheme. Med J Aust 2001;174:209-10.
3. World Trade Organization. Declaration on the TRIPS agreement and public health. Fourth WTO Ministerial Conference, Doha, Qatar, 9-14 November 2001. http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm (accessed 11 May 2004).
4. The US-Australia Free Trade Agreement (FTA). The intellectual property provisions report of the Industry Functional Advisory Committee on Intellectual Property. Rights for trade policy matters (IFAC-3). www.ustr.gov/new/fta/ Australia/advisor/ifac03.pdf (accessed 17 Mar 2004).